Key result
Metoprolol therapy for 6 months did not improve cardiac output response to stress compared to placebo in patients with cirrhotic cardiomyopathy.
Why the study?
Does metoprolol improve cardiac output response to stress in patients with cirrhotic cardiomyopathy?
RCT (n=78)
randomly assigned
Does metoprolol improve cardiac output response to stress in patients with cirrhotic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Six months of metoprolol therapy did not significantly improve heart function or morphology in patients with cirrhotic cardiomyopathy compared to placebo.
BACKGROUND: Cirrhotic cardiomyopathy is characterized by an attenuated contractile response to stress. Long-term exposure of β-adrenergic receptors to persistently high levels of catecholamines has been implicated in its pathogenesis. We hypothesized that β-blockade with metoprolol could reverse the changes in heart function and morphology in cirrhotic cardiomyopathy. PATIENTS AND METHODS: In this prospective randomized trial, we included 78 patients aged between 18 and 60 years with abnormal cardiac output response under dobutamine stress echocardiography, without primary cardiac disease or a history of alcohol intake. Patients were assigned randomly to receive metoprolol or placebo for 6 months. The primary endpoint was the improvement in cardiac output response to stress, measured by an increase in the left ventricle stroke volume more than 30%. RESULTS: Three (7.3%) patients in the metoprolol group and nine (24.3%) patients in the placebo group showed improved stroke volume (P=0.057). Diastolic dysfunction was found in two (4.8%) patients before and in five (15.6%) patients after therapy in the metoprolol group, and in 10 (27%) patients before and nine (31%) patients after therapy in the placebo group (P=0.67). After treatment, no echocardiography parameter of morphology was significantly different between metoprolol or placebo groups. No significant differences were observed in noradrenaline, plasma renin activity, and troponin levels between groups. Cirrhosis-related clinical events, including hospitalizations and mortality, were not significantly different between the two groups. Six months of therapy with β-blocker did not ameliorate heart function and morphology in patients with cirrhotic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Silvestre et al. (2018) conducted an RCT in cirrhotic cardiomyopathy (n=78). metoprolol vs. placebo was evaluated on improvement in cardiac output response to stress, measured by an increase in the left ventricle stroke volume more than 30% (p=0.057). Metoprolol therapy for 6 months did not improve cardiac output response to stress compared to placebo in patients with cirrhotic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: